Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter and year ended December 31, 2025 after the market close on Tuesday, March 3 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 3.

Business Wire • Feb 17, 2026

Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure

Arcturus Therapeutics now centers on ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency), with Covid assets as secondary cash support. ARCT is priced as a busted biotech with optionality; cash runway extends to 2028, but clinical and regulatory risks remain significant. ARCT-032's 12-week trial and ARCT-810's FDA alignment are key re-rating catalysts; both programs face pivotal data and regulatory endpoints.

Seeking Alpha • Feb 12, 2026

Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 5:15 p.m. Pacific Time. About Arcturus Found.

Business Wire • Jan 8, 2026

ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know

Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.

Zacks Investment Research • Dec 1, 2025

Arcturus Therapeutics to Attend Upcoming Investor Conference

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conference: Piper Sandler 37th Annual Healthcare Conference (Fireside Chat) Tuesday, December 2, 2025 (12:30 p.m. ET) About Arcturus Founded in 2013 and based i.

Business Wire • Nov 24, 2025

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. ( ARCT ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Neda Safarzadeh - Vice President and Head of IR/PR & Marketing Joseph Payne - Founder, President, CEO & Director Andrew Sassine - CFO & Director Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co., Research Division Jake Batchelder - William Blair & Company L.L.C., Research Division Boran Wang - Guggenheim Securities, LLC, Research Division Angela Qian - Canaccord Genuity Corp., Research Division Kuan-Hung Lin - Wells Fargo Securities, LLC, Research Division Joohwan Kim Thomas Shrader - BTIG, LLC, Research Division Yale Jen - Laidlaw & Company (UK) Ltd.

Seeking Alpha • Nov 11, 2025

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

NEWTOWN, Pa. , Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Arcturus Therapeutics Holdings Inc. ("Arcturus") (NASDAQ: ARCT), resulting from allegations of providing potentially misleading business information to the investing public.

PRNewsWire • Nov 10, 2025

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to a loss of $0.26 per share a year ago.

Zacks Investment Research • Nov 10, 2025

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the third quarter ended September 30, 2025, and provided corporate updates. “We were pleased to share the initial findings of ARCT-032 clinical activity with the CF community last month at the N.

Business Wire • Nov 10, 2025

Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Nov 4, 2025